Merck: molnupiravir demonstrates efficacy against Covid
(CercleFinance.com) - Merck and Ridgeback Biotherapeutics today announced that molnupiravir reduces the risk of hospitalization or death by approximately 50% in adult patients at risk who have mild-to-moderate COVID-19.
These results were obtained in an interim analysis of this investigational oral antiviral drug in a phase III trial.
No deaths were reported in patients who received molnupiravir after 29 days, compared to eight deaths in patients who received placebo.
Based on these results, Merck plans to submit an emergency use application for molnupiravir to the FDA and plans to submit marketing applications to other regulatory agencies around the world.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
These results were obtained in an interim analysis of this investigational oral antiviral drug in a phase III trial.
No deaths were reported in patients who received molnupiravir after 29 days, compared to eight deaths in patients who received placebo.
Based on these results, Merck plans to submit an emergency use application for molnupiravir to the FDA and plans to submit marketing applications to other regulatory agencies around the world.
Copyright (c) 2021 CercleFinance.com. All rights reserved.